MedTrace Logo

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

NCT00314613 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-12-02

No results posted yet for this study

Summary

Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment.

Conditions

Interventions

DRUG

Antipsychotic/Risperidone Consta

Sponsors & Collaborators

Principal Investigators

  • William H Wilson, PhD · Duke University

  • Joseph P McEvoy, MD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00314613 on ClinicalTrials.gov